

- [16] FIORENTINO F, BONO S, PIZZUTI F, et al. The importance of determining the limit of detection of non-invasive prenatal testing methods [J]. *Prenatal diagnosis*, 2016, 36(4): 304-311.
- [17] ASHOOR G, SYNGELAKI A, POON L C, et al. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: relation to maternal and fetal characteristics [J]. *Ultrasound in obstetrics & gynecology*, 2013, 41(1): 26-32.
- [18] NORTON M E, JACOBSSON B, SWAMY G K, et al. Cell-free DNA analysis for noninvasive examination of trisomy [J]. *The New England journal of medicine*, 2015, 372(17): 1589-1597.
- [19] CHAN N, SMET M E, SANDOW R, et al. Implications of failure to achieve a result from prenatal maternal serum cell-free DNA testing: a historical cohort study [J]. *BJOG: an international journal of obstetrics and gynaecology*, 2018, 125(7): 848-855.
- [20] PERGAMENT E, CUCKLE H, ZIMMERMANN B, et al. Single-Nucleotide Polymorphism-Based Noninvasive Prenatal Screening in a High-Risk and Low-Risk Cohort [J]. *Obstetrics & Gynecology*, 2014, 124(2): 210-218.
- [21] BELLAI-DUSSAULT K, MENG L, HOWLEY H, et al. Cytogenetic outcomes following a failed cell-free DNA screen: a population-based retrospective cohort study of 35, 146 singleton pregnancies [J]. *American journal of obstetrics and gynecology*, 2023, 229(2): 168.e1-168.e8.
- [22] BECKING E C, WIRJOSOEKARTO S A M, SCHEFFER P G, et al. Low fetal fraction in cell-free DNA testing is associated with adverse pregnancy outcome: Analysis of a subcohort of the TRIDENT-2 study [J]. *Prenatal diagnosis*, 2021, 41(10): 1296-1304.
- [23] CLAPP M A, BERRY M, SHOOK L L, et al. Low Fetal Fraction and Birth Weight in Women with Negative First-Trimester Cell-Free DNA Screening [J]. *American journal of perinatology*, 2020, 37(1): 86-91.
- [24] SCHEFFER P G, WIRJOSOEKARTO S A M, BECKING E C, et al. Association between low fetal fraction in cell-free DNA testing and adverse pregnancy outcome: A systematic review [J]. *Prenatal diagnosis*, 2021, 41(10): 1287-1295.

(收稿日期:2023-08-25)

编辑:刘邓浩


## · 视频导读 ·

## 无创产前检测临床应用的标准化

李金明

(国家卫生健康委临床检验中心 临床分子与免疫室,北京 100730)

DOI: 10.13470/j.cnki.cjpd.2023.03.014



来自国家卫生健康委员会临床检验中心副主任兼临床分子与免疫室主任李金明教授给我们带来了“无创产前检测临床应用如何标准化”的讲座,他从标准化与质量保证的关键环节,分子检测科研与临床应用之间的异同,临床有效性与临床预期用途,分析前标本采集的重要性,性能验证与性能确认以及结果报告与解释六个方面给我们

进行了详细阐述。从每一个详细的细节让我们了解了实验室质量管理的“灵魂”,以及遗传咨询的流程,作为分子遗传咨询师应该了解的内容及 NIPT 遗传咨询的关键点。